Most Read Articles
6 days ago
Regular practice of yoga postures confers benefits for glucose control, oxidative stress, inflammatory response, and sleep quality in patients with type 2 diabetes, a study has found.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
6 days ago
Women with central adiposity, regardless of menopausal status, are at risk of developing breast cancer, according to a study.

Injectable cabotegravir-rilpivirine sustains benefit in HIV patients, with or without oral lead-in

Audrey Abella
10 Nov 2020

An oral lead-in (OLI) regimen consisting of cabotegravir + rilpivirine (CAB+RPV) did not seem to have an effect on HIV patients who switched from a daily oral dolutegravir/abacavir/lamivudine (ABC/DTG/3TC) regimen to a monthly injectable CAB+RPV long-acting (LA) therapeutic regimen, given the similar efficacy, safety, and tolerability profiles observed with or without OLI, according to the 124-week results of the phase III FLAIR* trial presented at HIV Glasgow 2020.

“[These findings suggest] that CAB+RPV LA, with or without OLI, is a well-tolerated and effective maintenance therapy [in this setting],” said the researchers.

These results come on the heels of the 96-week FLAIR results reflecting the noninferiority of the monthly injectable CAB+RPV regimen to oral ABC/DTG/3TC therapy. [CROI 2020, abstract 482]

ART-naive participants who have achieved virological suppression (HIV-1 RNA <50 copies/mL) with ABC/DTG/3TC during a 20-week induction phase were included in the FLAIR maintenance phase (n=566). These patients were randomized 1:1 to either continue with ABC/DTG/3TC or switch to LA. Prior to transitioning, participants who switched to LA were given an OLI of CAB+RPV QD for 4 weeks.

At week 100, patients receiving oral ABC/DTG/3TC therapy entered the extension switch phase, wherein they were given the option to withdraw from their current regimen or switch to LA therapy – either directly (direct-to-inject [DTI] arm; n=111) or with a 4-week OLI (OLI arm; n=121). [HIV Glasgow 2020, abstract O414]

At week 112, one patient in the DTI arm had confirmed virological failure (ie, two consecutive HIV-1 RNA 200 copies/mL). By week 124, one participant in the DTI arm and another in the OLI arm had HIV-1 RNA 50 copies/mL.

Nonetheless, a majority of the participants in both the DTI and the OLI arms maintained virological suppression (99 percent and 93 percent, respectively) at week 124, as per FDA Snapshot algorithm.

Adverse events (AEs) leading to treatment discontinuation were uncommon in both the DTI and the OLI arms (n=0 and 2, respectively). Only one patient in the DTI arm discontinued owing to a reported lack of efficacy, while five from the OLI arm withdrew due to other reasons.

The most common AE in the DTI and the OLI arms was injection site reactions (n=576 and 338, respectively), which were mostly mild in severity (n=478 and 271, respectively). The rates of serious AEs were comparable between the DTI and the OLI arms (n=4 and 5, respectively). There was only one report of a grade 4 drug-related AE (ie, mixed cellularity Hodgkin’s lymphoma) occurring in the DTI arm. “Overall, CAB+RPV LA was well-tolerated,” noted the researchers.

Given the sustained virologic suppression in almost all participants and the favourable safety and tolerability profiles observed in both study arms in the extension switch phase, these findings suggest that the switch to a monthly injectable CAB+RPV regimen maintains it effect regardless of the presence or absence of an OLI, they said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Regular practice of yoga postures confers benefits for glucose control, oxidative stress, inflammatory response, and sleep quality in patients with type 2 diabetes, a study has found.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
6 days ago
Women with central adiposity, regardless of menopausal status, are at risk of developing breast cancer, according to a study.